A study to evaluate the effect of ETAZEO supplementation on sleep quality
- Conditions
- Improvement of sleep quality in participants with insomniaNervous System Diseases
- Registration Number
- ISRCTN60603080
- Lead Sponsor
- INNOVATION LABO Sciences Co., Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
1. Healthy non-smoker Asian male and female subjects between 25-65 years old (inclusive)
2. Presence of chronic disturbed sleep (PSQI >5)
3. Presence of chronic snoring. A patient is considered a chronic snorer if his/her bedmate/roommate reported snoring more than 5 days per week and if this is corroborated by medical analysis performed in the patient’s own home. The result of the respiratory polygraphy should indicate the presence of snoring during at least 30% of the nocturnal period.
4. Have a regular roommate or bedmate to submit information
5. Subjects available during the whole period of study (1 month)
1. Subjects with sleep apnoea
2. High-risk professions and/or controlling dangerous machines
3. Moderate or severe somnolence during day time
4. Coronary cardiopathy, acute vascular disease (less than three months), chronic and severe obstructive pulmonary disease, and chronic treatment with theophyllines
5. Temporo-mandibular joint problems or periodontitis
6. Mandibular protrusion capacity less than 6 mm and/or less than 10 teeth in each jaw
7. Severe cognitive disorders and/or patients whose answers to the questionnaires will be altered by chronic and severe diseases
8. Pregnancy (since the third month of pregnancy to 3 months after birth delivery)
9. Patients on prolonged medication(more than 6 weeks) with sleep medication, corticosteroids, antidepressants, anticholinergics, antipsychotic drugs, etc. or any other drugs that may have an influence on the outcome of the study
10. Pregnant/lactating women
11. Subjects who cannot agree to refrain from alcohol consumption during the study period
12. Alcoholics and/or drug abusers
13. Subjects having history of psychiatric disorders that may impair the ability to provide written informed consent
14. Patients who have completed participation in any other clinical trials during the past 3 months
15. Any other conditions that the Principal Investigator thinks may jeopardize the study outcomes
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method